This report was first published by Endpoints News. To see the original version, click here
The negative reaction to the impending departure of Sanofi CEO Paul Hudson, and Merck KGaA leader Belén Garijo as his replacement, is perhaps surprising given the French company’s muted performance under Hudson’s leadership.
Sanofi’s shares fell about 3% in Paris and 4% in New York, a cold shoulder that may simply reflect the scale of the challenge that Garijo faces when she takes the reins in late April. She’ll have less than five years before the company’s immunological juggernaut Dupixent goes generic.
您已阅读13%（599字），剩余87%（3907字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。